ES2186153T3 - Sulfato de 5-alfa-pregnan-3-beta-ol-20-ona para el tratamiento de tumores y de los trastornos del snc. - Google Patents

Sulfato de 5-alfa-pregnan-3-beta-ol-20-ona para el tratamiento de tumores y de los trastornos del snc.

Info

Publication number
ES2186153T3
ES2186153T3 ES98918789T ES98918789T ES2186153T3 ES 2186153 T3 ES2186153 T3 ES 2186153T3 ES 98918789 T ES98918789 T ES 98918789T ES 98918789 T ES98918789 T ES 98918789T ES 2186153 T3 ES2186153 T3 ES 2186153T3
Authority
ES
Spain
Prior art keywords
pregnan
sulfate
ona
alfa
tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98918789T
Other languages
English (en)
Inventor
Michael Z Kagan
Syed Muzafar Shah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Application granted granted Critical
Publication of ES2186153T3 publication Critical patent/ES2186153T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La invención suministra un procedimiento para suministrar terapia progestacional a un mamífero que tenga necesidad de la misma, el procedimiento comprende la administración de una cantidad progestacionalmente efectiva de una sal farmacológicamente aceptable de 5-alfa-pregnan-3beta-ol-20-ona 3-sulfato éster a dicho mamífero.
ES98918789T 1997-05-02 1998-04-28 Sulfato de 5-alfa-pregnan-3-beta-ol-20-ona para el tratamiento de tumores y de los trastornos del snc. Expired - Lifetime ES2186153T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85056797A 1997-05-02 1997-05-02

Publications (1)

Publication Number Publication Date
ES2186153T3 true ES2186153T3 (es) 2003-05-01

Family

ID=25308504

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98918789T Expired - Lifetime ES2186153T3 (es) 1997-05-02 1998-04-28 Sulfato de 5-alfa-pregnan-3-beta-ol-20-ona para el tratamiento de tumores y de los trastornos del snc.

Country Status (15)

Country Link
EP (1) EP0981349B1 (es)
JP (1) JP2001525807A (es)
KR (1) KR20010012157A (es)
CN (1) CN1254283A (es)
AR (1) AR012638A1 (es)
AT (1) ATE227130T1 (es)
AU (1) AU739146B2 (es)
BR (1) BR9809376A (es)
CA (1) CA2289006A1 (es)
DE (1) DE69809223T2 (es)
DK (1) DK0981349T3 (es)
ES (1) ES2186153T3 (es)
PT (1) PT981349E (es)
WO (1) WO1998050042A1 (es)
ZA (1) ZA983705B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2321728C (en) 1998-03-11 2008-12-09 Torbjorn Backstrom Epiallopregnanolone in the treatment of cns disorders
SE0104423D0 (sv) * 2001-12-27 2001-12-27 Umecrine Ab Pregnane steroids and their use in the treatment of CNS disorders
US7572780B2 (en) 2003-01-21 2009-08-11 Dimera, Incorporated Method and kit for reducing the symptoms of peripheral vascular disease
PT2030622E (pt) 2005-03-24 2011-06-02 Univ Emory Indicação da dose de progesterona no tratamento de um traumatismo crânio-encefálico
US7473687B2 (en) 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
WO2006117592A1 (en) * 2005-04-29 2006-11-09 Inserm Methods of modulating nuclear receptors
ES2566765T3 (es) 2010-01-14 2016-04-15 Asarina Pharma Ab Una composición farmacéutica que contiene 3-beta-hidroxi-5-alfa-pregnan-20-ona con propiedades de almacenamiento y solubilidad mejoradas

Also Published As

Publication number Publication date
JP2001525807A (ja) 2001-12-11
AU739146B2 (en) 2001-10-04
EP0981349A1 (en) 2000-03-01
BR9809376A (pt) 2000-07-04
ATE227130T1 (de) 2002-11-15
ZA983705B (en) 1999-11-01
CN1254283A (zh) 2000-05-24
DK0981349T3 (da) 2003-03-10
PT981349E (pt) 2003-01-31
DE69809223D1 (de) 2002-12-12
KR20010012157A (ko) 2001-02-15
AR012638A1 (es) 2000-11-08
CA2289006A1 (en) 1998-11-12
EP0981349B1 (en) 2002-11-06
AU7164798A (en) 1998-11-27
DE69809223T2 (de) 2003-07-24
WO1998050042A1 (en) 1998-11-12

Similar Documents

Publication Publication Date Title
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
DE69434211D1 (de) Phenylacetate und derivate, allein oder in kombination mit anderen verbindungen, zur behandlung von neoplastischen und anderen erkrankungen
ES2150663T3 (es) Tratamiento de la incontinencia urinaria utilizando (s)-oxibutinina y (s)-desetiloxibutinina.
UY26693A1 (es) Una composición farmacéutica y procedimiento de tratamiento de enfermedades de disfunción cognitiva en un mamífero
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
BG105534A (en) 5ht1 means and method for the treatment of migraine
MY119375A (en) Treatment of tinnitus using neuroprotective agents
MX9302038A (es) Metodo para el tratamiento del cancer por una terapia conjunta con derivados de 2-halometilideno y un agente antineoplasico especifico de fase m o fase s.
PA8467401A1 (es) Procedimiento para tratar la insuficiencia cardiaca
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
NO20003313D0 (no) Terapeutiske midler
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
ES2186153T3 (es) Sulfato de 5-alfa-pregnan-3-beta-ol-20-ona para el tratamiento de tumores y de los trastornos del snc.
FR2767526B1 (fr) Composes bi-aromatiques relies par un radical heteroethynylene et compositions pharmaceutiques et cosmetiques les contenant
DK0799618T3 (da) Anvendelse af alpha1-adrenoreceptor-antagonister i fremstillingen af et medikament til forebyggelsen og behandlingen af cancer
AR002191A1 (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion, procedimiento para su preparacion
PT1019068E (pt) Formulações terapêuticas contendo veneno de serpente e/ou insecto para a profilaxia e terapia de neoplasmas
AR023464A1 (es) Usos novedosos de la proteina ox2 de mamifero y reactivos relacionados
BR0012121A (pt) Derivado de aminotetralina para terapia de doenças cardiovasculares
AR018321A1 (es) Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
PA8480401A1 (es) Un metodo para la prevencion del inicio del asma
AR005866A1 (es) Composicion farmaceutica antioxidante
CO5170459A1 (es) Terapia transdermica con agonistas-antagonistas de estrogenos len-ol, administrados mediante medios transdermicos
AR010344A1 (es) Uso de equilenina o una sal farmaceuticamente aceptable del ester de equilenina-3-sulfato para la manufactura de un medicamento util para inhibir otratar patologias inducidas por los radicales libres y composiciones farmaceuticas
AR010336A1 (es) Uso de 17 alfa-dihidroequilenina o una sal farmaceuticamente aceptable del ester 17 alfa-dihidroequilenina-3-sulfato para la manufactura de un medicamentoutil para inhibir o tratar patologias inducidas por los radicales libres y una composicion farmaceutica.